CSL Ltd (ASX: CSL) shares have slid slightly into the red in Wednesday lunchtime trade.

At the time of writing, the ASX biotech stock is down around 0.2% and is changing hands at $172 a piece.

Despite the softer share price today, CSL shares are still up a huge 38% over the past month alone, have rebounded 86% from a multi-year low in early-June, and are now roughly flat for the year-to-date.

What has driven CSL shares higher over the past month?

After a difficult 18 months, including several market and company headwinds, it looks like investor sentiment around CSL shares have finally turned a corner and the worst could finally be over. And it appears to be driven by several tailwinds.

It looks like investors finally realised that the CSL share sell-off was overdone, and the shares were selling too cheap compared to the underlying business. 

At the same time, it looks like ASX healthcare shares have come back into favor after a significant sell-off. CSL hasn’t moved in isolation, either. Australian healthcare stocks have staged a major recovery, with the healthcare index rising more than 20% in a month recently.

The S&P/ASX 200 Health Care Index (ASX: XHJ) has jumped 17% higher over the past month as investors rotate back into the sector.

CSL shares were boosted even higher after it posted an impressive FY26 result in mid-August.

CSL reported total revenue of US$15.8 billion and NPAT of US$2.6 billion. It also recorded a net loss after tax of US$2.6 billion for FY26, coming from pre-tax impairments and restructuring costs. 

CSL management describes FY26 as a ‘reset year’, with FY27 marking a return to growth.

The result came in way ahead of guidance and investors rushed to snap up the shares.

Are the shares a buy for September?

I think there is a lot of potential for the company to grow over the next few years. CSL is operating in a high-growth market, and its blood plasma division dominates the market for rare blood disorders and immunoglobulin products.

The company’s growth initiatives are clearly working. But it’s likely it will take a while longer to see the financial benefits.

At the moment, forecasts suggest the experts are mostly on the fence. But after the latest price spike, many think we’ll see a downside ahead. 

Market Index data shows that brokers are split between a buy and a hold rating on CSL shares. The $153.21 average target price now implies a potential 11% downside, at the time of writing.

Sentiment is similar on TradingView. The majority (10 out of 18) have a hold rating on the stock. However, the other eight rate CSL shares as a buy/strong buy.

The average $168.13 target price is higher, but it still implies a potential downside of around 2%, at the time of writing.

I’d consider adding them to my portfolio in September, but I’d be wary of exactly how much upside, if any, it left after CSL shares rallied in August.

The post CSL shares rebound 86%: Is the ASX biotech stock a buy, sell or hold for September? appeared first on The Motley Fool Australia.

More reading

• The 5 best ASX 200 stocks to buy and hold in August revealed
• Top 3 ASX shares to buy in September 2026
• CSL shares are up more than 40% in a month. What just happened in the US?
• 5 things reporting season taught ASX investors about FY27
• Where will CSL shares be in 12 months? Brokers weigh in

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) closed up 1.1% in the month just past, with Coles Group Ltd (ASX: COL) shares trailing those gains while Woolworths Group Ltd (ASX: WOW) shares just edged out the benchmark index.

Closing on 31 August trading for $24.04 apiece, Coles shares slipped 0.2% over the month.

Woolworths shares went the other way, gaining 1.4% to close the month at $40.31 each.

Both of the ASX 200 supermarket giants reported their full year FY 2026 results in August.

Here’s what’s been happening.

Woolworths shares march higher in August

Woolworths shares were in focus on 26 August following the release of the company’s FY 2026 results.

The company achieved solid growth over the year, with sales of $71.54 billion up 3.6% from FY 2025. Earnings before interest, taxes, depreciation and amortisation (EBITDA) (before significant items) increased by 6.7% year on year to $6.09 billion.

And on the bottom line, Woolworths reported a net profit after tax (NPAT) of $1.60 billion, up 15.4% (before significant items).

Passive income investors were rewarded with a 15.6% increase in the final fully franked Woolworths dividend, which came out to 52 cents per share.

“Sales momentum together with strong productivity and cost discipline has delivered solid EBIT growth with an increased contribution from all trading segments,” Woolworths CEO Amanda Bardwell said.

Woolworths shares closed up 3.4% on the day of the results release.

Coles shares jump on results, slip over the month

Coles released its own FY 2026 results on 25 August.

Over the 12 months, Coles reported sales revenue of $45.58 billion, up a 2.8% year-on-year. Earnings before interest and tax (EBIT) of $2.32 billion were up 9.9% (excluding significant items).

On the bottom line, Coles NPAT came out to $1.26 billion (excluding significant items) up 13.7% from FY 2025.

Coles declare a 37-cent per share fully-franked final dividend, up 15% from the prior final dividend payout.

If you want to bank the final Coles dividend, there’s still time. But not much!

To grab that passive income, you’ll need to own shares at market close today. Coles shares trade ex-dividend on 3 September.

Coles shares closed up 4.9% on the day of the results release.

How have the ASX 200 supermarkets been tracking in 2026?

In morning trade today Coles shares are changing hands for $23.74 apiece, up 11.3% year to date.

Woolworths shares are trading for $39.36 each, up 33.7% in 2026.

The post Coles versus Woolworth shares: Which ASX supermarket giant outperformed in August? appeared first on The Motley Fool Australia.

More reading

• How to build an ASX portfolio you can stick with for 10 years
• Don’t panic if these 9 ASX 200 shares fall today
• 5 things to watch on the ASX 200 on Tuesday
• How much superannuation do I need to earn $90,000 per year in passive income?
• Up 12%: Is there still value in Coles shares?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The team at Shaw and Partners have used the recent reporting season as an opportunity to have another look at some of the companies they cover, with two in particular standing out as presenting some possible large upside.

Let’s have a look at the companies they like.

Beamtree Holdings Ltd (ASX: BMT)

Beamtree is a healthcare technology company which, in its own words, “applies deep clinical, coding and data expertise combined with AI to help hospitals and pathology labs improve clinical quality, coding accuracy, and reimbursement outcomes”.

The company said in a recent shareholder update that it had undertaken a strategic review which led to it refining its product mix, reshaping its cost base and strengthening its executive team.

The company added:

Going forward, we are focusing our investment on the products with strongest customer resonance, margin potential and capacity for innovation, namely our market leading Diagnostics product (Rippledown), our Coding solutions (PICQ and PICQ Audit, RISQ) and our Analytics platform. This year we are launching our Autonomous Coding Solutions (ACS) product and our Autonomous Data Entry (ADE) product with selected customers.

Shaw and Partners in its research note on the company said the company’s full year result of $29.2 million in revenue and negative EBITDA of $3.5 million was broadly as expected.

The broker said the business had a solid foundation to grow from, with execution now the key.

They have reduced their price target on the company from 30 cents to 25 cents, however this is still well above the current level of 10 cents.

NobleOak Life Ltd (ASX: NOL)

This small cap life insurance provider delivered a net profit of $14.1 million in FY26, up 98% while its in-force premiums grew 18% to $549.2 million.

The company’s Chief Executive Officer Anthony Brown said it was a good year, with the company achieving strong market share gains.

He added:

We are executing our growth strategy and during the year launched new partnerships and products including a new alliance with nib, one of Australia’s largest private health insurers, which is delivering encouraging early results and is expected to accelerate in FY27. Disciplined underwriting, ongoing investment in technology and AI, and a relentless focus on our customer continue to underpin our performance. As we transition from a Friendly Society to a Life Company, we are well positioned and well capitalised to deliver our next growth phase.

Shaw and Partners said NobleOak beat its guidance for both in-force premiums and underlying net profit.

The broker has a price target of $3 on the shares, compared to $1.23 currently.

The post 2 ASX small caps which could rise 140% to %150 appeared first on The Motley Fool Australia.

More reading

• 3 fantastic ASX ETFs for Aussie investors in September
• This ASX 200 stock has fallen 32% from its high. Is it finally cheap?
• Santos versus Woodside shares: Which ASX energy stock outperformed in August?
• Could this ASX tech company really rise 180%?
• Corporate Travel Management swings to profit as earnings jump in FY26

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Beamtree. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.